Custom GxP-compliant software for pharmaceutical manufacturers, CROs, and biotech companies — from clinical trial data management and electronic batch records to DSCSA serialization and LIMS integration. Every system built to FDA 21 CFR Part 11, EU Annex 11, and GAMP 5 standards with full Computer System Validation documentation. Average drug development costs $2.6 billion and takes 10–15 years. The software that supports that pipeline cannot be an afterthought.
GxP is not one regulation — it is a family of regulations that govern every phase of drug development, manufacturing, and distribution. GMP (Good Manufacturing Practice) governs production and quality control of pharmaceutical products under 21 CFR Parts 210 and 211. GLP (Good Laboratory Practice) governs non-clinical laboratory studies under 21 CFR Part 58. GCP (Good Clinical Practice) governs clinical trials involving human subjects under ICH E6(R2). Each has distinct requirements for how software systems must behave, how data must be captured and stored, and how validation must be documented. A clinical trial EDC system operating under GCP has fundamentally different validation requirements than an electronic batch record system operating under GMP — and both differ from a LIMS operating under GLP. Software vendors who treat GxP as a single checkbox do not understand the regulatory landscape.
FDA 21 CFR Part 11 establishes the criteria under which electronic records and electronic signatures are considered trustworthy, reliable, and equivalent to paper records and handwritten signatures. The rule applies to any electronic record that is created, modified, maintained, archived, retrieved, or transmitted under any FDA regulation. In practice, this means every pharmaceutical software system must implement audit trails that capture who changed what, when, and why — with the previous value preserved. Electronic signatures must use at least two distinct identification components (such as user ID and password), must be linked to their respective electronic records, and must include the printed name of the signer, the date and time of the signature, and the meaning of the signature (approval, review, responsibility). Session controls must ensure that only authorized individuals can use the system, with automatic logoff after periods of inactivity. These are not optional features to add later — they are foundational architectural requirements that must be designed into the system from the first line of code.
GAMP 5 — Good Automated Manufacturing Practice version 5, published by ISPE — provides the risk-based framework for validating computerized systems in GxP-regulated environments. GAMP 5 categorizes software into five categories that determine the validation approach. Category 1 covers infrastructure software like operating systems and database engines. Category 3 covers non-configured products used as-is. Category 4 covers configured products where functionality is selected through configuration rather than custom code. Category 5 covers custom applications — bespoke software built to specific user requirements. Categories 4 and 5 require the most rigorous validation because they carry the highest risk of introducing errors specific to the regulated process. When FreedomDev builds pharmaceutical software, we are building Category 5 systems. That means full lifecycle validation: User Requirements Specification (URS), Functional Requirements Specification (FRS), Design Specification (DS), and a complete V-model testing approach with Installation Qualification (IQ), Operational Qualification (OQ), and Performance Qualification (PQ). Every requirement traces forward to a test case and every test case traces back to a requirement. There are no gaps in the traceability matrix.
Data integrity in pharmaceutical software is governed by the ALCOA+ principles, established by FDA and adopted globally by EMA, WHO, PIC/S, and MHRA. ALCOA+ requires that data be Attributable (who performed the action and when), Legible (readable and permanent throughout the retention period), Contemporaneous (recorded at the time of the activity), Original (the first-capture record or a certified true copy), and Accurate (free from errors, or if errors exist, they are documented with corrections that do not obscure the original entry). The '+' extends these principles to include Complete (all data including repeat or reanalysis results), Consistent (chronologically sequenced with timestamps that make sense), Enduring (recorded on permanent media, not whiteboards or sticky notes), and Available (accessible for review throughout the retention period). Every pharmaceutical software system FreedomDev builds enforces ALCOA+ at the database level — not as a policy overlay, but as a technical constraint that makes non-compliant data entry architecturally impossible. Audit trails are append-only. Original values are never overwritten. Timestamps are server-generated and cannot be modified by users. Signatures are cryptographically linked to the record content they attest to.
We specialize in building custom software for your industry. Tell us what you're dealing with.
Most pharmaceutical companies operate software systems that were built before 21 CFR Part 11 requirements were well understood or that accumulated technical debt during years of incremental modifications. These systems frequently lack compliant audit trails — either recording only that a change occurred without capturing the previous value, or storing audit data in logs that can be modified or deleted by database administrators. Electronic signature implementations often fail to meet the two-component identification requirement or do not bind signatures to specific record versions. Session management may lack automatic logoff, or logoff timers may be set to impractically long intervals that allow unauthorized access. Retrofitting Part 11 compliance into a system not designed for it is not a configuration change — it requires re-architecting the data layer, the authentication system, and the audit infrastructure. FDA Warning Letters citing Part 11 deficiencies have increased steadily, and the agency's Data Integrity and Compliance With Drug CGMP guidance (2018) made clear that data integrity failures — including software-related failures — are treated as CGMP violations.
A single Phase III clinical trial generates an average of 3.6 million data points across hundreds of sites and thousands of patients. Clinical data flows through Electronic Data Capture (EDC) systems, Interactive Response Technology (IRT) for randomization and drug supply, safety databases for adverse event reporting, and central and local laboratory information systems — all of which must maintain audit-trailed, GCP-compliant records. The challenge is not just volume but integration: EDC data must reconcile with safety database entries, lab data must map to case report form fields, and all of it must produce a submission-ready dataset that meets CDISC standards (CDASH for collection, SDTM for tabulation, ADaM for analysis). Most CROs and sponsors operate a patchwork of Medidata Rave, Oracle Clinical, Veeva Vault CDMS, or legacy in-house systems that do not integrate cleanly. When a Phase III trial spans 200 sites in 30 countries, data reconciliation consumes 20–30% of clinical data management effort — time and money that could be eliminated with proper system integration and standardized data pipelines.
The Drug Supply Chain Security Act (DSCSA), signed into law in 2013 with phased enforcement milestones, requires that every prescription pharmaceutical package in the US supply chain carry a unique product identifier — serialized at the unit level with a National Drug Code (NDC), serial number, lot number, and expiration date encoded in a 2D barcode. As of November 2023, the enhanced requirements mandate that manufacturers, wholesale distributors, dispensers, and repackagers exchange Transaction Information (TI), Transaction History (TH), and Transaction Statements (TS) electronically for every transaction. The FDA has granted stabilization periods for certain requirements, but the direction is clear: full electronic, interoperable, unit-level tracing across the entire US pharmaceutical supply chain. Many mid-size pharmaceutical manufacturers and contract manufacturers (CMOs) are still running serialization systems that handle line-level encoding but lack the enterprise integration to exchange EPCIS events with trading partners, aggregate parent-child relationships for case and pallet levels, or respond to verification requests through the FDA-recognized systems. Building or integrating a compliant serialization system requires deep understanding of GS1 standards, EPCIS event architecture, and the specific data exchange requirements of major wholesale distributors like McKesson, AmerisourceBergen, and Cardinal Health.
Every GxP-regulated software system requires Computer System Validation (CSV) before it can be used in production. For GAMP 5 Category 5 (custom) software, this means producing and executing a complete validation lifecycle: Validation Plan, User Requirements Specification, Functional Requirements Specification, Design Specification, traceability matrix linking requirements to test cases, Installation Qualification (IQ) confirming the system is installed correctly in the target environment, Operational Qualification (OQ) confirming each function operates according to its specification, and Performance Qualification (PQ) confirming the system performs as intended under realistic operating conditions. The validation documentation for a moderately complex custom pharmaceutical system can run 500–2,000 pages. When the system changes — a bug fix, a feature addition, a security patch — the change control process requires impact assessment, updated risk analysis, regression testing, and re-execution of affected IQ/OQ/PQ protocols. Many pharmaceutical companies avoid custom software entirely because the validation overhead makes every change expensive and slow. This is a solvable problem: validation-aware development practices — requirements traceability built into the development workflow, automated qualification scripts, and modular architecture that isolates validated components — reduce the validation burden by 40–60% compared to traditional approaches.
Laboratory Information Management Systems (LIMS) in pharmaceutical environments — platforms like LabWare, Thermo Fisher SampleManager, or STARLIMS — manage sample tracking, instrument integration, method management, specification checking, and certificate of analysis generation. But a LIMS does not operate in isolation. In a GMP manufacturing environment, the LIMS must integrate with the Manufacturing Execution System (MES) to receive in-process and finished product samples triggered by batch production events. It must integrate with the Quality Management System (QMS) to route out-of-specification (OOS) results into deviation and CAPA workflows. It must integrate with the Electronic Document Management System (EDMS) to access current versions of test methods and specifications. And it must feed results back to the ERP for batch release decisions. Each of these integrations must maintain GxP data integrity — audit trails must span system boundaries, electronic signatures must be valid across platforms, and data must not be transformable in transit without documentation. Most LIMS implementations stall not because of the LIMS configuration itself, but because the integration architecture between LIMS, MES, QMS, EDMS, and ERP was underestimated or treated as an afterthought.
Pharmaceutical batch records are the legal evidence that a drug product was manufactured according to its approved process. Paper batch records — still the norm at a surprising number of mid-size pharmaceutical manufacturers — create well-documented problems: transcription errors during manual data entry (industry estimates suggest 1–5% error rates in paper-based records), review-by-exception that misses critical deviations because the reviewer is fatigued after reading the 200th page, version control failures when operators use obsolete forms, and batch release delays of 2–5 days while QA reviews paper binders. Electronic Batch Records (EBR) eliminate these problems by enforcing process execution in real time — operators follow guided workflows on tablets or terminals, data is captured from instruments and equipment automatically where possible, and deviations trigger immediate alerts rather than being discovered during post-production review. But EBR implementation in pharma is not a simple digitization project. The EBR system is classified as a GxP Category 5 custom application that requires full CSV, must integrate with process control systems (DCS/SCADA) for automated data capture, and must implement 21 CFR Part 11 compliant electronic signatures at every critical step — weighing, dispensing, equipment setup, in-process checks, environmental monitoring, and final release.
Our previous vendor delivered a system that passed functional testing but failed our first mock FDA inspection — the audit trail did not capture the previous value on record modifications, which is a fundamental Part 11 requirement. FreedomDev rebuilt the data layer with immutable audit trails and ALCOA+ enforcement at the architecture level. When FDA conducted a pre-approval inspection six months later, the investigator spent 30 minutes reviewing our electronic records and moved on. That is the difference between software that works and software that is compliant.
Purpose-built pharmaceutical software designed with FDA 21 CFR Part 11 and EU Annex 11 compliance as foundational architecture — not a bolt-on module. Every system includes immutable append-only audit trails that capture the who, what, when, and why of every data modification with the original value preserved. Electronic signatures implement two-component identification with signature meaning (approval, review, verification) cryptographically bound to the specific record version being signed. Role-based access control with segregation of duties ensures that the person who performs an action cannot also approve it. Session management enforces automatic logoff, password complexity, and account lockout policies aligned with your corporate security standards. Data integrity is enforced at the database level through server-generated timestamps, referential integrity constraints, and prevention of direct database modification outside the application layer. ALCOA+ principles are not a policy — they are a technical constraint built into every table, every form, and every workflow. FreedomDev delivers all GAMP 5 Category 5 validation documentation as part of the development lifecycle: URS, FRS, DS, traceability matrix, IQ/OQ/PQ protocols and executed results, and a Validation Summary Report ready for your QA unit's review and approval.
Learn moreCustom clinical data management systems and integration layers that connect your EDC platform — whether Medidata Rave, Oracle Clinical, Veeva Vault CDMS, or a proprietary system — to downstream safety databases, central laboratory systems, IRT platforms, and regulatory submission pipelines. We build CDISC-compliant data transformation engines that convert collected clinical data (CDASH) into submission-ready tabulation datasets (SDTM) and analysis datasets (ADaM) with full traceability from source to submission. For sponsors managing multi-study programs, we build cross-trial data repositories that enable aggregate safety analysis, signal detection, and portfolio-level reporting. For CROs managing multiple sponsor datasets, we build multi-tenant data management platforms with sponsor-specific configurations, blinding controls, and data access policies. Every system is GCP-compliant with complete audit trails, electronic signatures for data query resolution, and role-based access that enforces the principle that clinical data managers, medical monitors, and statisticians see only the data appropriate to their role. Reconciliation workflows between EDC and safety databases — the process that consumes 20–30% of clinical data management effort in most organizations — are automated with configurable matching algorithms and exception-based review.
Learn moreEnd-to-end pharmaceutical serialization systems that meet DSCSA requirements from packaging line to trading partner. At the line level: integration with serialization equipment (Antares Vision, Optel, Systech) to generate, apply, and verify unique product identifiers on each saleable unit, with aggregation tracking through case and pallet levels. At the enterprise level: a serialization repository that manages serial number pools, tracks aggregation hierarchies (unit to case to pallet to shipment), and stores the complete chain of custody for every serialized unit. At the trading partner level: EPCIS-based event exchange with wholesale distributors, 3PLs, and dispensers — including commissioning, packing, shipping, receiving, and decommissioning events in GS1-compliant formats. The system handles verification requests (is this serial number legitimate, was it shipped to this location, has it been previously dispensed) and supports the FDA's enhanced verification requirements. For contract manufacturers producing for multiple brand owners, we build multi-tenant serialization platforms that manage separate serial number pools, branding configurations, and trading partner relationships for each client while sharing common line-level infrastructure. All serialization data is maintained with 21 CFR Part 11 compliant audit trails and is available for FDA inspection for the required 6-year retention period.
Learn moreIntegration architecture that connects your Laboratory Information Management System — LabWare, Thermo Fisher SampleManager, STARLIMS, or others — to the manufacturing, quality, and business systems it must communicate with. MES-to-LIMS integration automates sample creation: when a batch production event triggers an in-process or finished product test, the LIMS receives the sample request with batch context (product code, batch number, manufacturing step, specifications to test against) without manual entry. LIMS-to-QMS integration routes out-of-specification results directly into your deviation and CAPA workflow — an OOS result in the LIMS creates a deviation record in your QMS within minutes, not days. LIMS-to-EDMS integration ensures that analysts always access the current approved version of test methods, specifications, and standard operating procedures. LIMS-to-ERP integration feeds test results into batch disposition workflows so that QA can make release decisions with complete quality data visible in a single interface. Every integration maintains GxP data integrity across system boundaries: audit trails document data in transit, electronic signatures are valid across platforms, and data transformation rules are validated and version-controlled. FreedomDev has integrated LabWare and SampleManager with SAP, Oracle, Veeva Vault Quality, MasterControl, and every major pharmaceutical MES platform.
Learn moreCustom Electronic Batch Record systems that replace paper manufacturing records with guided, enforced, and data-rich digital workflows. Operators follow step-by-step instructions on tablets or HMI terminals — weighing, dispensing, equipment setup, in-process checks, and yield calculations are guided by the system and enforced in sequence. Data from instruments (balances, pH meters, particle counters), equipment (reactors, granulators, tablet presses, filling lines), and environmental monitoring systems feeds directly into the batch record without manual transcription. Critical process parameters are captured automatically and compared against validated ranges in real time — deviations trigger immediate alerts and require documented corrective actions before the process can continue. Electronic signatures at every critical step meet 21 CFR Part 11 requirements with biometric or two-factor authentication options for high-risk signing events. Review-by-exception replaces page-by-page review: QA reviewers see a dashboard of deviations, out-of-range values, and manual entries rather than reading 200 pages of normal results. Batch release cycles that took 3–5 days with paper records drop to hours. The system maintains complete batch genealogy — every raw material lot, every equipment unit, every operator, every environmental reading linked to the finished product batch for full traceability.
Learn moreAnalytics and reporting platforms built on pharmaceutical manufacturing, quality, and clinical data — with the regulatory awareness that generic BI tools lack. Manufacturing analytics: batch yield trending, right-first-time rates, deviation frequency by product line and root cause category, equipment utilization and cleaning turnaround times, and Annual Product Review (APR) report generation with statistical process control charts that meet FDA expectations. Quality analytics: CAPA effectiveness metrics, OOS investigation trending, supplier quality scorecards, and complaint analysis with signal detection algorithms that identify emerging product quality issues before they become field actions. Clinical analytics: enrollment tracking, data query cycle times, protocol deviation trending, and site performance scorecards. Regulatory submission support: generation of CTD Module 3 manufacturing data summaries, stability trending with shelf-life estimation, and pharmacovigilance aggregate reports (PSURs/PBRERs). Every dashboard and report includes the metadata regulators expect: data source, extraction date, query logic, and user access audit trail. Reports generated for regulatory submission are locked, versioned, and signed with 21 CFR Part 11 compliant electronic signatures. FreedomDev builds these platforms on modern BI stacks (Power BI, Tableau, or custom) with validated data pipelines that ensure the numbers in the dashboard match the numbers in the source systems — a validation requirement that generic BI implementations consistently overlook.
Learn more| Metric | FreedomDev | Generic SaaS |
|---|---|---|
| 21 CFR Part 11 Compliance | Architected from day one — immutable audit trails, bound e-signatures, RBAC | Bolted on after development — audit gaps, unsigned records, admin overrides |
| CSV Documentation | Validation artifacts delivered as part of development lifecycle (URS through PQ) | Validation treated as a separate project after software is built — costly rework |
| Change Control Turnaround | Impact assessment, regression testing, and re-qualification in days | Weeks-to-months for vendor change requests; validation backlog grows |
| ALCOA+ Data Integrity | Enforced at database architecture level — non-compliant entry is impossible | Policy-based — relies on user behavior and SOP compliance |
| System Integration | Validated data pipelines across LIMS, MES, QMS, EDMS, and ERP | Point-to-point integrations that break when one system upgrades |
| Regulatory Inspection Readiness | Complete traceability matrix, executed protocols, and audit trail reports on demand | Scramble to compile validation documentation before an announced inspection |
Schedule a technical consultation with our senior architects.
Make your software work for you. Let's build a sensible solution for Pharmaceutical.
